DBPapers
DOI: 10.5593/SGEM2016/HB63/S08.037

MODULATING EFFECTS OF BIOTECHNOLOGICAL PREPARATION ROPREN® IN B-AMYLOID-(25-35) RAT MODEL OF ALZHEIMER’S DISEASE IN FEMALE RATS WITH ESTROGEN DEFICIENCY ON DEPRESSION-LIKE BEHAVIOR

J. Fedotova, O. Volkova
Friday 11 November 2016

References: 16th International Multidisciplinary Scientific GeoConference SGEM 2016, SGEM Vienna GREEN Extended Scientific Sessions, www.sgemviennagreen.org, SGEM2016 Conference Proceedings, ISBN 978-619-7105-79-7 / ISSN 1314-2704, 2 - 5 November, 2016, Book 6 Vol. 3, 285-292pp, DOI: 10.5593/SGEM2016/HB63/S08.037

ABSTRACT
Alzheimer’s disease (AD) is a multifactorial and, until now, irreversible neurodegenerative disease with an aetiology and pathological pathway that remain largely unknown. Neuropsychiatric symptoms, mainly anxiety and depression, are exceedingly prevalent in AD. Affective-related behavior increases the severity of cognitive decline in AD patients. Ropren® can be such candidate substance for treatment of AD in women with an imbalance of estrogen. Ropren® substance (pure polyprenols) was isolated from the green verdure of Picea abies (L.) Karst. Nowadays, polyprenols have been extensively studied as multifunctional agents for the prevention and treatment of cancer, liver pathology, cardiovascular diseases, and cognitive impairment. The present preclinical study was designed to examine the effects of prolonged Ropren® administration (8.6 mg/kg, per os, 28 days, once daily) on depression-like behavior in a β-amyloid (25-35) rat model of Alzheimer’s disease following ovariectomy. The experimental model was created by intracerebroventricular injection of β-amyloid (25-35) into ovariectomized (OVX) rats and OVX rats with 17β-estradiol (17β-E2, 5.0 μg/rat, subcutaneously, once daily, 28 days) supplementation. Ropren® was administered to the OVX rats and OVX rats treated with 17β-E2. Depression-like behavior was assessed in the forced swimming test (FST) and the spontaneous locomotor activity was assessed using the open field test. The corticosterone and estradiol levels in the blood serum before and after FST were measured in all experimental groups. Treatment with Ropren® significantly decreased the immobility time of OVX rats with β-amyloid (25-35)-induced amnesia in the forced swimming test. Co-administration of Ropren® with 17β-E2 exerted a markedly synergistic antidepressant-like effect in the OVX rats with β-amyloid (25-35)-induced amnesia on the same model of depression-like behavior testing. Ropren® administered alone or together with 17Β-E2 significantly enhanced crossing, frequency of rearing and grooming of the OVX rats with β-amyloid (25-35)-induced amnesia in the open field test. Moreover, Ropren® administered alone or together with 17β-E2 significantly decreased the elevated corticosterone levels in the blood serum of OVX rats with β-amyloid (25-35)-induced amnesia following the forced swimming test. These results indicate that Ropren® has a marked antidepressant-like effect in the experimental model of Alzheimer’s disease in female rats with estrogen deficiency.

Keywords: Alzheimer’s disease, polyprenols, Ropren®, depression, ovariectomy, estradiol

PAPER DOI: 10.5593/SGEM2016/HB63/S08.037, MODULATING EFFECTS OF BIOTECHNOLOGICAL PREPARATION ROPREN® IN B-AMYLOID-(25-35) RAT MODEL OF ALZHEIMER’S DISEASE IN FEMALE RATS WITH ESTROGEN DEFICIENCY ON DEPRESSION-LIKE BEHAVIOR

35 EURO ADD TO CART


Your cart ( items)

Subtotal:
Tax cost ():
Shipping cost:
Total:
Checkout Empty